In summary, alterations in the methylome of IDH mutant cartilage tumors are associated with tumor progression and this study shows that targeting of epigenetic regulators could be a potential therapeutic strategy for both IDH wildtype and IDH mutant chondrosarcoma patients. This evidence concerns the gene IDH1 and chondrogenic neoplasm.